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Abstract
Extracellular vesicles (EVs) have emerged as important mediators of intercellular communi-
cation and as possible therapeutic agents in inflammation-mediated demyelinating dis-
eases, including multiple sclerosis (MS). In the present study, we investigated whether
intravenously administered EVs derived from mesenchymal stem cells (MSCs) from human
adipose tissue might mediate recovery in Theiler’s murine encephalomyelitis virus (TMEV)-
induced demyelinating disease, a progressive model of MS. SJL/J mice were subjected to
EV treatment once the disease was established. We found that intravenous EV administra-
tion improved motor deficits, reduced brain atrophy, increased cell proliferation in the sub-
ventricular zone and decreased inflammatory infiltrates in the spinal cord in mice infected
with TMEV. EV treatment was also capable of modulating neuroinflammation, given glial
fibrillary acidic protein and Iba-1 staining were reduced in the brain, whereas myelin protein
expression was increased. Changes in the morphology of microglial cells in the spinal cord
suggest that EVs also modulate the activation state of microglia. The clear reduction in
plasma cytokine levels, mainly in the Th1 and Th17 phenotypes, in TMEV mice treated with
EVs confirms the immunomodulatory ability of intravenous EVs. According to our results,
EV administration attenuates motor deficits through immunomodulatory actions, diminishing
brain atrophy and promoting remyelination. Further studies are necessary to establish EV
delivery as a possible therapy for the neurodegenerative phase of MS.
Introduction
Multiple Sclerosis (MS) is an inflammation-mediated demyelinating disease of the central ner-
vous system (CNS) and the leading cause of nontraumatic disability in young adults [1]. Classi-
cally, MS has been considered a demyelinating disease affecting white matter; however, there
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is growing evidence that axonal/neuronal damage and grey matter loss/neurodegeneration
play a central role and contribute to sequelae [2–4].
The majority of available treatments for patients with MS are immune modulators because
most research has been conducted using the experimental autoimmune encephalomyelitis
(EAE) animal model. However, recent data have highlighted the importance of considering
the neurodegenerative component of the disease that is reproduced in the model of Theiler’s
murine encephalomyelitis virus (TMEV) [5–7]. TMEV infection in SJL/J mice causes chronic
progressive demyelinating disease, with characteristics that resemble progressive forms of MS
that entail brain atrophy [8]. Lesions induced in this animal model have both an inflammatory
component and a neurodegenerative component, achieving a close resemblance to MS and
therefore making the model suitable for analysing the effects of drugs that promote the repair
of CNS lesions. In MS, inflammation and degeneration appear to occur simultaneously; a fea-
ture that is reflected in the TMEV model, which also reproduces the neurodegenerative com-
ponent of the disease observed during the delayed phase in most patients and in progressive
forms of the disease [9].
Recent data have shown that peripheral circulating cells produce factors that promote in
vivo CNS myelination via extracellular vesicle (EV) signalling [10,11]. EVs are small, 40–120
nm membrane vesicles of endocytic origin produced by virtually all cells in the body, including
mesenchymal stem cells (MSCs), which are capable of improving functional recovery, fibre
tract integrity, axonal sprouting and white matter repair markers in neurological diseases
[12–14].
Among the various types of stem cells used for the treatment of neurodegenerative diseases,
MSCs appear to have aroused the greatest interest as promising candidates. Previous studies
using adipose tissue-derived mesenchymal stem cells (ADMSCs) have shown their therapeutic
potential in the EAE model by mediating immunomodulation and enhancing brain repair
mechanisms [15]. Nevertheless, given that only a small proportion of injected stem cells can
reach, engraft and differentiate at the lesion’s site suggests that the beneficial effect of stem
cells can be indirect and depends on their paracrine activity [16]. Stem cells produce a wide
spectrum of EVs, which contain cytokines, chemokines, growth factors, proteins and nucleic
acids that might affect cell-to-cell communication. From a translational point of view, interest
in EVs has increased in recent years, given they can easily be produced in large amounts and at
lower cost than stem cells and can be stored for further use. Increasing evidence suggests that
EVs display anti-inflammatory properties, reducing the number of activated inflammatory
microglial cells, supporting oligodendrocytes and protecting neurons [11–14]. However, there
is as yet no evidence regarding the therapeutic potential of EVs during the neurodegenerative
phase of MS.
Here, we hypothesise that the administration of EVs derived from human ADMSCs might
mediate repair mechanisms in CNS damage and promote recovery in TMEV-induced demye-
linating disease (TMEV-IDD).
Materials and methods
Mesenchymal stem cell EV generation, isolation and characterisation
Human ADMSCs (Tebu-Bio, Spain) were thawed and suspended in conventional culture
medium with Dulbecco’s Modified Eagle Medium (DMEM) (Gibco Laboratory, Grand Island,
NY, USA) containing 20% fetal bovine serum (FBS; PAA Laboratories, GmbH, Pasching, Aus-
tria) and penicillin–streptomycin (Sigma-Aldrich, St Louis, MO, USA) in 75 cm2 tissue culture
flasks (Nunc, Roskilde, Denmark). When the cells reached 90% confluence, the conventional
culture medium was replaced with an EV-depleted FBS culture medium (System Biosciences,
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Mountain View, CA, USA). The cells were then cultured for an additional 24 hours, the media
were collected and the EVs were isolated by ultracentrifugation. To discard the cells, the medium
was centrifuged for 10 minutes at 300 x g. A second centrifugation for 10 minutes at 2000 x g was
needed to discard the dead cells. Another centrifugation for 30 minutes at 10,000 x g was used to
discard cell debris. To obtain EVs, the supernatant was centrifuged 70 minutes at 100,000 x g.
Finally, we deleted the contaminating proteins of the EV pellet by centrifugation for 70 minutes at
100,000 x g and resuspended it in phosphate-buffered saline (PBS) (Sigma-Aldrich) [17].
For characterisation and further administration, the purified EVs were eluted in PBS and
stored at -20˚C until use. We have quantified the EVs by measuring the total protein concen-
tration using a bicinchoninic acid commercial kit (Thermo Scientific, Waltham, MA, USA).
The EVs were characterised by studying morphology and size (<100 nm), using electron
microscopy and NanoSight (NanoSight Ltd, UK); their phenotype expressing CD81 and CD63
markers was examined by western blot technique. The EV phenotype was determined by
immunofluorescence using a specific lipophilic tracer, CellTrackerTM CM-DiI (Invitrogen,
Oregon, USA), and was then colabelled with apoptosis-linked gene-2 interacting protein X
(ALIX) (1:250, Abcam), a specific EV antibody.
Animals and Theiler’s virus infection
All animal care and experimental procedures were performed in accordance with EU (2010/
63/EU) and governmental guidelines (Royal Decree 53/2013 BOE n˚34 and Comunidad de
Madrid: ES 280790000184) and were approved by the Ethics Committee on Animal Experi-
mentation of the Cajal Institute (protocol number: 2013/03 CEEA-IC). All studies involving
animals are reported in accordance with the Animal Research: Reporting of in vivo Experi-
ments guidelines for reporting experiments involving animals [18]. A total of 33 animals were
used in the experiments described here.
TMEV-IDD-susceptible female SJL/J mice from Envigo (Barcelona, Spain) were maintained
at our in-house colony (Cajal Institute, Madrid, Spain) on a 12-hour light/dark cycle with ad
libitum access to food and water. Four- to six-week-old mice were intracranially inoculated in
the right hemisphere with 2 × 106 plaque-forming units of the Daniel strain of TMEV diluted in
30 μL of DMEM supplemented with 10% fetal calf serum (FCS) [19]. The sham-operated mice
received 30 μL of DMEM + 10% FCS alone. On day 60 postinfection, 25 μg of EVs were admin-
istered to the treatment group (TMEV-EVs) through the tail vein. A saline injection of the same
volume was delivered to the sham and nontreated TMEV (TMEV-VH) animals. Mice were dis-
tributed into the sham (n = 7), TMEV-VH (n = 10) and TMEV-EVs (n = 10) groups. The allo-
cation of each animal to an experimental group was performed on the basis of a simple random
choice: throwing a die (less than/equal to two: control; three or four: vehicle; and more than
four: treatment). Details of the experimental protocol are shown in Fig 1.
EV biodistribution
For the evaluation of EV biodistribution at 2 hours after intravenous administration, an addi-
tional six animals were used, which were divided into two groups: sham group (n = 3) and
TMEV-EVs (n = 3). TAPA1 marker levels (CD81) (1:750, Abcam) were observed in the brain
as well as in samples from the peripheral organs, such as the lungs, spleen and liver. A colabel-
ling of EVs (CD63) with glial fibrillary acid protein (GFAP) (1:400, Millipore) and neuronal
specific nuclear protein (NeuN) (1:100, Millipore) was made by immunofluorescence. The EV
phenotype was determined by immunofluorescence with a specific lipophilic tracer, Cell-
TrackerTM CM-DiI (Invitrogen, Carlsbad, CA, USA), and then colabelled with ALIX (1:250,
Abcam). Images were acquired as a maximum confocal projection using a LEICA TCS SPE
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spectral confocal microscope (Leica Microsystems, Heidelberg, Germany) and analysed using
LAS AF software (Leica). Mean fluorescence intensity was measured by the NIS-Element AR
(Nikon) 4.5 Program.
Behavioural analysis: Spontaneous motor, activity memory and object
recognition test
Behavioural tests were evaluated on day 15 after treatment. For spontaneous locomotor activ-
ity, an activity cage coupled with a Digiscan analyser was used (Digiscan Activity Monitoring
System, Omnitech Electronics Inc, Columbus, OH, USA). The number of times the animals
broke the vertical sensor beams was automatically measured in two 5-minute sessions, as pre-
viously described [20]. Memory was evaluated using passive avoidance (Passive Avoidance
Cage for Mice, Harvard Apparatus, MA, US), a fear-aggravated test in which mice learn to
avoid a noninvasive foot shock. Briefly, the cage is composed of two compartments (light and
dark). The test was conducted over 3 days: The animals were free to explore both compart-
ments during the first day, preferring to stay on the dark side due to their rodent nature; on
the second day, a noninvasive foot shock was delivered in the dark compartment; and on the
third day, the latency to enter the dark compartment was measured.
In vivo magnetic resonance imaging
Ventricular size was analysed at 15 days after treatment by MRI (Bruker Pharmascan, Ettlin-
gen, Germany) [21], using 7 Tesla horizontal bore magnets and T2-weighted (T2-W) spin-
echo anatomical images acquired with a rapid acquisition with relaxation enhancement
(RARE) sequence in axial orientations, with the following parameters: number of echo images,
2 (TE: 29.54 ms and 88.61 ms); TR, 3000 ms; RARE factor, 4; Av, 3; FOV, 3.5 cm; acquisition
matrix, 256 × 256 corresponding to an in-plane resolution of 137 × 137 μm2; slice thickness,
1.00 mm without gap; and number of slices, 16. For this procedure, the animals were anesthe-
tised with a 2% isoflurane-oxygen mixture in an induction chamber and the flow of anaesthetic
gas was constantly regulated to maintain a breathing rate of 50 +/− 20 bpm.
Ventricular size was calculated as a percentage of whole brain volume in single-slice regions
of interest. For quantification, all the images were processed using the Image J 1.52D program
(NIH software, Bethesda, MD, USA).
Fig 1. Experimental protocol scheme. EVs were isolated from human adipose tissue-derived MSCs and subsequently
characterised. Four- to six-week-old female SJL/J mice were inoculated intracerebrally into the right hemisphere with
2 × 106 plaque-forming units of the Daniel strain of TMEV. On day 60 postinfection, treatment (saline or EVs) was
administered through the tail vein. Distribution of mice: sham (n = 7), TMEV-VH (n = 10) and TMEV-EVs (n = 10).
On day 75 postinfection, we evaluated mouse behaviour and performed imaging, biomarker, histological and
molecular studies. Abbreviations: TMEV: Theiler’s murine encephalomyelitis virus; EVs: extracellular vesicles;
TMEV-EVs: Theiler’s murine encephalomyelitis virus with EV treatment; TMEV-VH: Theiler’s murine
encephalomyelitis virus with saline treatment; MRI: magnetic resonance imaging; IH: immunohistochemistry; IF:
immunofluorescence; WB: western blot.
https://doi.org/10.1371/journal.pone.0202590.g001
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Tissue processing, immunohistochemistry, immunofluorescence and
western blot
The mice were anesthetised with pentobarbital (50 mg/kg body weight, intraperitoneally) and
perfused with saline. The animals’ brains and spinal cords were fixed overnight in 4% parafor-
maldehyde prepared in 0.1 M phosphate buffer (PB), and cryoprotected in 30% sucrose solu-
tion in 0.1 M PB, then mounted in optimal cutting temperature compound (Sakura Finetek,
CA, USA) and stored at -80˚C. Coronal brain and spinal cord sections (30 μm thick) were
obtained using a Leica CM1950 cryostat (Leica) and processed for the following studies.
For the immunohistochemistry, the inflammatory infiltrate studies were obtained by hema-
toxylin and eosin stain. Slides were immersed 1 minute in hematoxylin and 3 minutes in eosin
previous to water washes. Finally, they were dehydrated and coverslipped with Depex. Infil-
trates were observed in spinal cord sections, using a 20× objective lens, and were processed by
image analysis software (Image-Pro Plus 4.1, Media Cybernetics). The number of lesions were
evaluated on a scale of 0 to 4, the score reflecting the number of infiltrates in the thoracic spinal
cord sections. A score of 4 reflects the largest number of infiltrates with all the intermediate
scores (1, 2, and 3) to define the increase in the density of infiltrates in the spinal cord tissue.
In the cell proliferation studies, slides were treated with citrate buffer (pH 6) at 95˚C for 10
minutes; after inhibiting endogenous peroxidase, they were blocked for 1 hour with 3% normal
goat serum (Vector Laboratories) at room temperature. The slides were incubated overnight
with primary polyclonal antibody anti-Ki67 (1:100; Chemicon, Temecula, CA, USA). After
having been washed in Tris-buffered saline (TBS), they were incubated with biotinylated uni-
versal secondary antibody and in streptavidin/peroxidase (Vector Laboratories, Burlingame,
CA, USA). The sections were again washed in TBS and incubated with chromogen 3,3-diami-
nobenzidine (DAB) (Invitrogen). Finally, they were dehydrated and coverslipped. Cell prolif-
eration was analysed in the brain sections corresponding to the subventricular zone (SVZ) of
each animal. The number of positive cells was counted, using a 40× objective lens, and was
processed by image analysis software (Image-Pro Plus 4.1, Media Cybernetics).
For immunofluorescence of the brain, we used antibodies against 2’,3’-cyclic-nucleotide 3’-
phosphodiesterase (CNPase) (1:500, Sigma-Aldrich), GFAP (1:400, Millipore), Iba-1 (1:1000,
Millipore) and myelin basic protein (MBP) (1:200, Abcam). In the spinal cord sections, we
used CNPase (1:500, Sigma-Aldrich) and Iba-1 (1:1000, Millipore). Anti-mouse and anti-rab-
bit Alexa Fluor 488 (1:750, Invitrogen) were used as secondary antibodies. All sections were
mounted with H-1200 VectaShield mounting medium for fluorescence with 4’,6-diamidino-
2-phenylindole (ATOM). To quantify the levels of both markers, mean fluorescence intensity
was measured under the confocal microscope using a 40x objective lens in a LEICA TCS SPE
spectral confocal microscope (Leica), and the confocal images were analysed using LEICA soft-
ware LAS AF, version 2.0.1 Build 2043. Images were acquired as a maximum confocal projec-
tion and analysed using LAS AF software (Leica).
For western blot analysis, the same antibodies (CNPase [1:1000, Sigma-Aldrich], GFAP
[1:500, Millipore], Iba-1 [1:1000, Millipore] and MBP [1:100, Abcam]) were used. Units were
normalised based on ß-actin levels (1:400, Sigma-Aldrich). Normalised optical density was cal-
culated using the Alliance imaging system (UVItec Ltd, Cambridge, UK) (n = 4 animals per
group).
Determination of cytokine plasma levels by multiplex ELISA assay
Plasma samples were analysed by multiplex enzyme-linked immunosorbent assay (Affymetrix,
eBioscience). An array of 12 cytokines was analysed (Mouse ProcartaPlex Panel Th1/Th2
+ IL17A): granulocyte-macrophage colony-stimulating factor (GM-CSF), interferon gamma
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(IFNγ), tumour necrosis factor alpha (TNFα) and interleukin (IL)-1β, IL-2, IL-4, IL-5, IL-6,
IL-12p70, IL-13, IL-17A and IL-18, using a Luminex—LX200 Analyzer (Luminex Corpora-
tion, Austin, TX, USA) and MILLIPLEX Analyst 5.1 software. Assay Sensitivity: GM-CSF: 0.19
pg/mL; IFNγ: 0.09 pg/mL; TNFα: 0.39 pg/mL; IL-1β: 0.14 pg/mL; IL-2: 0.10 pg/mL; IL-4: 0.03
pg/mL; IL-5: 0.32 pg/mL; IL-6: 0.21 pg/mL; IL-12p70: 0.21 pg/mL; IL-13: 0.16 pg/mL; IL-17A:
0.016 pg/mL; IL-18: 9.95 pg/mL.
Statistics
The data are expressed as mean ± standard deviation. A one-way analysis of variance
(ANOVA) followed by the Bonferroni post-hoc test, or a Kruskal–Wallis ANOVA followed by
the Mann–Whitney U test were used to determine statistical significance. Values of p< .05
were considered significant at a 95% confidence interval; the data were calculated using statis-
tical software programs IBM SPSS statistics 22 and GraphPad 7.0.
Results
EV characterisation and biodistribution
The EVs that we isolated came from a culture of 2x106 human ADMSCs. Per flask, we obtained
approximately 9 μg/ul of EVs. Regarding EV characterisation, EVs showed typical morphology
and size (<100 nm) by electron microscope (Fig 2A). EVs were detected by specific markers
(positive: CD81 and CD63; negative: albumin), using western blot assay (Fig 2B). We con-
firmed the size (<100 nm) with a 1,269e+010 particles/ml concentration using NanoSight (Fig
2C). Their phenotype was ALIX+ (EV-specific marker) according to immunofluorescence
(Fig 2D). EV biodistribution in the TMEV-infected mice was assessed by TAPA1/CD81 stain-
ing as a positive marker in the brain (top of Fig 2E). EVs (CD63) were found in the brain (bot-
tom of Fig 2E) as well as in the peripheral organs, such as the lungs, spleen and liver (Fig 2F),
using colabelling with cellular markers such as GFAP and NeuN, 2 hours after their intrave-
nous administration. Finally, we measured fluorescence intensity (arbitrary unit [A.U.]) in the
brain (3.11 ± 1.03 A.U.) and peripheral organs such as the lungs (3.86 ± 1.36 A.U.), spleen
(0.84 ± 0.26 A.U.) and liver (7.17 ± 0.91 A.U.).
Effects of EV treatment on mouse behaviour, brain atrophy imaging, spinal
cord inflammatory infiltrates and cell proliferation in the subventricular zone
The TMEV-infected mice showed diminished vertical activity in the chronic phase of the dis-
ease, consistent with other studies [20,22]. Activity-cage testing showed that the TMEV mice
treated with EVs (TMEV-EVs) displayed better motor activity than the TMEV-VH group; spe-
cifically, in the vertical activity (61.5 ± 7.88 vs. 21.3 ± 15.64, respectively; p< .05), number of
times stood on hind legs (27.67 ± 4.85 vs. 13.44 ± 4.48, respectively; p< .05) and time spent
standing on hind legs (19.56 ± 4.87 vs. 6.29 ± 2.36, respectively; p < .05). In the passive avoid-
ance memory test, mice showed a trend toward better performance in the TMEV-EVs group
(261 ± 79.31) compared with the TMEV-VH group (203.64 ± 114.87), without reaching statis-
tical significance (Fig 3A). Therefore, intravenously administered EVs improved motor func-
tion in TMEV mice. We then evaluated the effect of EV treatment on imaging brain atrophy;
thus, relative ventricular size in the coronal plane was evaluated for the sham, TMEV-VH and
TMEV-EVs groups, taking into account the size of the ventricles with respect to the total brain
size. The TMEV-EVs group showed that the ventricle size (0.020 ± 0.0011) was smaller than
that of the TMEV-VH group (0.039 ± 0.005) and similar to that observed in the sham group
(0.020 ± 0.0038) (Fig 3B).
Extracellular vesicles in an experimental model of multiple sclerosis
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In addition, we investigated the effect of EV treatment on spinal cord inflammatory infil-
trates and cell proliferation in the SVZ niche. In both the TMEV-VH and TMEV-EVs groups,
inflammatory infiltrates were located in the white matter of the spinal cord. The number of
lesions was significantly higher in the TMEV-VH group (2.38 ± 1.532) compared with the
TMEV-EVs group (1.19 ± 1.020; p< .05) (Fig 3C), suggesting that EV administration modu-
lates inflammation in TMEV mice.
Proliferative KI-67+ cells were observed in the TMEV-VH mice, in agreement with previous
studies showing increased cell proliferation in the SVZ in this model of MS [23,24]. The num-
ber of KI-67+ cells in the SVZ was significantly higher in the TMEV-EVs group (15.50 ± 2.759)
compared with the TMEV-VH group (9.40 ± 0.966; p< .05) and with the sham group (11 ±
4.726; p< .05), as shown in Fig 3D, indicating that intravenously administered EVs promote
cell proliferation in the SVZ.
Effects of EV treatment on glial marker and myelin protein expression in
the brain and spinal cord of TMEV mice
Brain immunofluorescence analysis at day 15 post-EV treatment (Fig 4A) showed that the
group of mice that intravenously received EVs exhibited a significant reduction in the fluores-
cence intensity of glial markers—GFAP for astrocytes (3.37 ± 1.80 A.U.) and Iba-1 for micro-
glia (1.30 ± 0.53 A.U.)—compared with the TMEV-VH group (8.34 ± 2.34 vs. 6.36 ± 0.75 A.U.,
respectively; p< .05). In addition, we observed a significant increase in myelin proteins such
as CNPase (36.02 ± 4.15 vs. 18.24 ± 5.14 A.U., respectively; p< .05) and MBP (14.57 ± 1.48 vs.
7.67 ± 4.43 A.U., respectively; p< .05) in the TMEV-EVs group compared with the TMEV-
VH mice (Fig 4A). The immunofluorescence data were confirmed by western blot analysis
because we found a significant reduction in GFAP in the brains of the TMEV-EVs mice
(0.52 ± 0.18 A.U.) compared with the TMEV-VH group (1.43 ± 0.36 A.U.; p = .009). Regarding
Iba-1 expression, the TMEV-EVs group also showed lower values (0.99 ± 0.10 A.U.) compared
with the TMEV-VH group (1.95 ± 0.28 A.U.; p = .004). Moreover, when comparing the TME-
V-EVs and TMEV-VH groups, there were higher levels of CNPase (1.14 ± 0.23 vs. 0.795 ± 0.04
A.U., respectively; p = .05) as well as of MBP (1.92 ± 0.06 vs. 1.30 ± 0.21 A.U., respectively; p =
.007) (Fig 4B). With respect to the spinal cord, we did not find significant differences between
the TMEV-EVs and TMEV-VH groups in any of the above markers by western blot: GFAP
(0.5 ± 0.06 vs. 0.49 ± 0.14 A.U., respectively); Iba-1 (0.65 ± 0.04 vs. 0.67 ± 0.04 A.U., respec-
tively); CNPase (0.51 ± 0.05 vs. 0.59 ± 0.09 A.U., respectively); and MBP (0.71 ± 0.11 vs. 0.42 ±
0.23 A.U., respectively); or by immunofluorescence (data not shown). Nevertheless, we noticed
some changes in the morphology of the microglial cells (Fig 4B), from cells with ramified pro-
cesses in sections from the sham mice to more rounded cells with short processes in sections
from the TMEV mice. This was clearly indicative of spinal cord neuroinflammation in the
Fig 2. EV characterisation and biodistribution after intravenous administration. EVs were characterised using various
techniques: (A) Electron microscope image. EVs with size smaller than 100 nm were observed by electron microscope. (B)
Western blot. Detection of EVs with specific markers (positive: CD81 and CD63; negative: albumin) by western blot assay. Negative
control samples are supernatant with debris and dead cells. The gels image was cropped. (C) Characteristics of particles. Size and
concentration of the particles detected in the sample EVs isolated and EVs-FBS (culture media) by NanoSight. (D) Phenotype of
EVs. Immunofluorescence of EVs labelled with DiI (red) and the specific EV marker antibody anti-ALIX (green). (E)
Biodistribution of the EVs in the brain. Top: after intravenous administration, EVs were observed in the brain by the TAPA-1
marker (green), using immunofluorescence. Bottom: Colabelling with EVs (green) and cellular markers (GFAP/NeuN) (red) in the
brain, using immunofluorescence. (F) Biodistribution of the EVs in peripheral organs. EVs were found in various peripheral
organs, such as the lungs, spleen and liver, by immunofluorescence (green). (G) EV quantification. Fluorescence intensity
quantification (arbitrary units) in brain and peripheral organs. Abbreviations: EVs: extracellular vesicles; human ADMSCs: human
adipose tissue-derived mesenchymal stem cells; EVs-FBS: extracellular vesicles -depleted FBS media; DiI: lipophilic Tracer
CellTrackerTM CM-DiI; GFAP: glial fibrillary acidic protein; NeuN: neuronal specific nuclear protein.
https://doi.org/10.1371/journal.pone.0202590.g002
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Fig 3. (A) Behavioural evaluation. Behaviour was evaluated by various tests: activity-cage, passive avoidance and object recognition (n = 7 animals in the
sham group; n = 10 animals each in the TMEV-VH and TMEV-EVs groups). Data are mean ± SD, p< .05. (B) Ventricular size. Qualitative and
quantitative analysis of T2-weighted MRI images showed significant differences in ventricle sizes (coronal) between the TMEV-VH and TMEV-EVs groups
(n = 4 animals per group). (C) Hematoxylin and eosin stain. Spinal cord sections, with hematoxylin and eosin stain, in which inflammatory infiltrates can
be observed (black arrows) in the TMEV-VH and TMEV-EVs groups (n = 4 animals per group). (D) Cell proliferation. KI-67-positive cells in the SVZ
(n = 10 animals per group). Data are mean ± SD, p< .05. Abbreviations: EVs: extracellular vesicles; SVZ: subventricular zone; TMEV: Theiler’s murine
encephalomyelitis virus; TMEV-EVs: Theiler’s murine encephalomyelitis virus with EV treatment; TMEV-VH: Theiler’s murine encephalomyelitis virus
with saline treatment.
https://doi.org/10.1371/journal.pone.0202590.g003
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TMEV-VH mice, in agreement with numerous other reports [25,26]. In the TMEV mice
treated with EVs, we found that the morphology of the microglial cells was similar to that
observed in the sham mice, suggesting that EV administration modulates inflammation in the
spinal cord of TMEV mice.
EV treatment reduces plasma cytokine levels in the TMEV model in the
chronic progressive phase
To determine whether the modulation of inflammation observed in the CNS after EV adminis-
tration also occurred at the systemic level in the chronic progressive phase of the disease, we
analysed the levels of 12 Th1/Th2 cytokines as well as IL17A in plasma obtained from the three
groups of mice. As shown Fig 5, there were significantly higher levels of all the cytokines tested
in the TMEV-VH group compared with the TMEV-EVs group: GM-CSF (8.98 ± 1.44 vs.
1.18 ± 0.02 pg/mL, respectively), IFNγ (314.91 ± 123.16 vs. 0.26 ± 0.05 pg/mL, respectively),
TNFα (263.34 ± 89.01 vs. 2.08 ± 0.18 pg/mL, respectively), IL-1β (86.63 ± 16.49 vs. 0.308 ±
0.02 pg/mL, respectively), IL-2 (3.26 ± 0.26 vs. 0.416 ± 0.02 pg/mL, respectively), IL-4 n.d.; IL-
5 (13.258 ± 3.92 vs. 1.05 ± 0.21 pg/mL, respectively), IL-6 (166.14 ± 6.47 vs. 3.80 ± 1.33 pg/mL,
respectively), IL-12p70 (6.54 ± 0.09 vs. 0.04 ± 0.01 pg/mL, respectively), IL-13 (3.88 ± 0.33 vs.
1.04 ± 0.05 pg/mL, respectively), IL-17A (41.83 ± 37.27 vs. 0.2 ± 0.04 pg/mL, respectively) and
IL-18 (666.14 ± 115.26 vs. 23 ± 4.05 pg/mL, respectively) (p<.05). As expected, we found sig-
nificant differences between the control sham mice and the TMEV-VH mice; the TMEV-VH
mice showing increased plasma levels of all the GM-CSF, IFNγ, TNFα, IL-1β, IL-2, IL-4, IL-5,
IL-6, IL-12p70, IL-13 and IL-18 cytokines. In addition, we detected a significant difference
(p<.05) in plasma levels of IFNγ and IL-12p70 between the sham and TMEV-EVs groups,
showing reduced levels of both cytokines in the TMEV-EVs mice (Fig 5). Interestingly, both,
pro- and anti-inflammatory cytokines, such as IL-5 and IL-13, were downregulated following
EV treatment, although to a different degree. The most relevant results correspond to IFNγ,
TNFα and IL-1βtogether with IL-18 of the IL-1 family, IL-6 and IL-12 p70 the bridge between
innate and acquired immunity, and IL-17 A, one of the main pathogenic cytokines in MS.
Discussion
The results of this study showed that intravenous EV administration was able to improve
motor deficits in the TMEV-IDD model, an experimental model of primary progressive MS.
We found that the treated group had better functional recovery than the mice receiving vehi-
cle. The group treated with EVs from ADMSCs also had higher levels of white matter-associ-
ated markers (CNPase and MBP) than the control group, suggesting that EV administration
might induce repair of white matter fibre tracts.
In this model, central atrophy accompanies the demyelinating condition [27]. Here, we
determined the rate of brain atrophy and its relationship to disability by the activity cage assay.
Our results demonstrated the development of significant brain atrophy in parallel with
Fig 4. Brain repair-associated markers after EV treatment at 2 weeks post-treatment. (A) Immunofluorescence of
brain repair markers. Significant difference in brain repair marker expression (GFAP, Iba-1, CNPase and MBP)
(green) between the TMEV-VH and TMEV-EVs groups by immunofluorescence (n = 4 animals per group). Data are
mean ± SD, p< .05. (B) Western blot. Brain repair marker expression (GFAP, Iba-1, CNPase and MBP) with their
quantifications by western blot. Data are mean ± SD, p< .05. (C) Immunofluorescence in spinal cord.
Morphological changes in microglia activation in spinal cord by immunofluorescence with Iba-1 (20X, 40X) (green).
EVs: extracellular vesicles; VH: vehicle; TMEV-EVs: Theiler’s murine encephalomyelitis virus with EV treatment;
TMEV-VH: Theiler’s murine encephalomyelitis virus with saline treatment; CNPase: 2’,3’-cyclic-nucleotide 3’-
phosphodiesterase; MBP: myelin basic protein; GFAP: glial fibrillary acidic protein.
https://doi.org/10.1371/journal.pone.0202590.g004
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impaired vertical activity. ADMSC administration is considered to be an appropriate thera-
peutic strategy because ADMSCs enhance the natural repair processes of the brain after injury
[28,29]. However, the mechanisms underlying these repair processes are still unknown. A
wealth of findings have shown the role of EVs in nerve regeneration, neuronal protection and
remyelination, indicating the possible therapeutic potential of these vesicles in neurological
diseases [11,13,14,30,31]. In our study, we have demonstrated that the intravenous administra-
tion of EVs from ADMSCs exerts therapeutic effects on the TMEV model, improving motor
disability and reducing brain atrophy. These beneficial effects were accompanied by a
decreased in the number of inflammatory infiltrates in the spinal cord and increased cell pro-
liferation in the SVZ, although at this time we do not comprehend the meaning of this increase
regarding putative repair mechanisms; further studies are being performed to shed light on
this issue. We report here a possible mechanism previously associated with ADMSC EV ther-
apy function, such as the modulation of neuroinflammation, consistent with many other
Fig 5. Plasma levels of cytokines analysed at the chronic phase and 2 weeks after EV treatment. The TMEV-VH group showed higher levels of these cytokines in
plasma compared with the treated group (n = 7 animals in the sham group; n = 7 animals in the TMEV-VH group and n = 12 animals in the TMEV-EVs group). Data
are mean ± SEM, p< .05 sham vs. TMEV-EVs; Δp< .05 TMEV-VH vs. TMEV-EVs; оp< .05 TMEV-VH vs. sham. Abbreviations: EVs: extracellular vesicles;
TMEV-EVs: Theiler’s murine encephalomyelitis virus with EV treatment; TMEV-VH: Theiler’s murine encephalomyelitis virus with saline treatment.
https://doi.org/10.1371/journal.pone.0202590.g005
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studies [31–33]. In this regard, EV administration reduced several glial markers—such as
GFAP for astrocytes and Iba-1 for microglia in the brain—as well as the morphologic charac-
teristics of microglial cells towards a less inflammatory phenotype within the spinal cord of
TMEV mice. Remarkably, the drastic reduction in plasma cytokine levels, mainly of the Th1
and Th17 phenotypes in TMEV mice treated with EVs, constitutes clear evidence for the
immunomodulatory ability of intravenous EVs. Cumulative evidence has indicated that sys-
temic cytokines might act as mediators of CNS damage, including demyelination, via neuroin-
flammatory pathways [34,35]. In addition, cytokines in the blood can alter peripheral immune
cells and promote interactions with the blood brain barrier (BBB), affecting peripheral mono-
cytes and T and B lymphocytes, inhibiting their entry into the CNS. There are numerous
examples that show how a modulatory effect on systemic immunity can affect the symptom-
atology in experimental models of MS [36]. Among others, the anti-inflammatory activity of
EVs from ADMSCs might underlie their benefits in our progressive MS model. Nevertheless,
at present we cannot determine the extent to which the downregulation of plasma cytokines
impacts on TMEV progression or the specific cellular target of their actions. We are unable to
establish unequivocally whether the beneficial effects we observed in the progressive MS
model are mediated by systemic immune modulation or by subsequent actions on neural cells.
Further studies are needed to identify the exact mechanisms of EV-induced improvement of
TMEV-IDD progression.
There remains an incomplete picture regarding the role of EVs in MS pathogenic mecha-
nisms, their importance as biomarkers and their potential as therapeutic targets. With respect
to therapeutic applications, understanding the in vivo biodistribution after systemic delivery is
of great relevance [37]. Despite intense research on the subject, few studies have analysed EV
biodistribution. Using fluorescently-labelled EVs, we observed an accumulation of green fluo-
rescence not only in various peripheral organs such as the lung, spleen and liver but also in the
brains of the TMEV mice at 2 hours after intravenous administration as a consequence of the
capacity to pass through the BBB. Our observations suggest that EVs could be one of the fac-
tors involved in the communication between the CNS and the peripheral immune system,
mediating the modulation of both central and systemic responses following brain TMEV
infection, as has been considered recently in other models of peripheral inflammation [32].
Due to the capacity of EVs to cross the BBB, they can be considered as therapeutic agents in
many clinical studies as a delivery system to transport RNA, protein and drug molecules. The
development of cell-free vesicle-based therapeutics is a particularly exciting application,
because they can recapitulate the modulatory and regenerative potential of cell-based therapies
without the intrinsic safety concerns connected with the administration of live cells. Regarding
clinical applications, there is as yet no gold standard method for high production of EVs for
patient treatment. However, the manufacture of the medicinal product should be performed
by companies specialised for this purpose. Once the EV treatment is prepared, it could be
stored at −80˚C for at least 90 days at the hospital until needed; however, storage at below
−70˚C is the most favourable condition for long-term preservation of fresh EVs for clinical
application and basic research [38]. EVs are considered an important diagnostic tool, given
they can be detected in biological fluids, they are very stable and their contents are protected
[39]. In this sense, vesicles have attracted great interest for their use as biomarkers, which has
led to the development of EV-based commercial diagnostic kits [40].
Conclusions
The present study is the first to demonstrate that intravenous administration of EVs derived
from human ADMSCs attenuates motor deficits through immunomodulatory actions,
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diminishing brain atrophy and promoting remyelination in a murine model of progressive
MS. Nevertheless, further studies are necessary to understand the complex molecular mecha-
nisms that might influence the efficacy of EV delivery as a possible therapy for the neurodegen-
erative phase of MS.
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